Report overview
The global AL Amyloidosis Therapeutics market was valued at US$ million in 2023 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2023, While China is to reach $ Million.
Chemotherapy Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of AL Amyloidosis Therapeutics include Janssen Pharmaceutical, Prothena, Alexion Pharmaceuticals, Oncopeptides AB, Bristol-Myers Squibb, GlaxoSmithKline Pharmaceuticals Ltd, Eidos Therapeutics, Inc., Corino Therapeutics, Inc. and Spectrum Pharmaceuticals, Inc., etc. in 2023, the global top five players have a share approximately % in terms of revenue.
The most common kind of systemic amyloidosis is the amyloid light chain (AL) amyloidosis, sometimes referred to as primary amyloidosis. Systemic light-chain (AL) amyloidosis was once thought to be an unstoppable deadly condition.
This report aims to provide a comprehensive presentation of the global market for AL Amyloidosis Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding AL Amyloidosis Therapeutics. This report contains market size and forecasts of AL Amyloidosis Therapeutics in global, including the following market information:
Global AL Amyloidosis Therapeutics Market Revenue, 2019-2024, 2025-2030, ($ millions)
Global top five companies in 2023 (%)
We surveyed the AL Amyloidosis Therapeutics companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global AL Amyloidosis Therapeutics Market, by Type, 2019-2024, 2025-2030 ($ millions)
Global AL Amyloidosis Therapeutics Market Segment Percentages, by Type, 2023 (%)
Chemotherapy
Supportive Care
Surgery
Stem Cell Transplant
Targeted Therapy
Global AL Amyloidosis Therapeutics Market, by Application, 2019-2024, 2025-2030 ($ millions)
Global AL Amyloidosis Therapeutics Market Segment Percentages, by Application, 2023 (%)
Hospitals
Clinics
Ambulatory Service Centres
Others
Global AL Amyloidosis Therapeutics Market, By Region and Country, 2019-2024, 2025-2030 ($ Millions)
Global AL Amyloidosis Therapeutics Market Segment Percentages, By Region and Country, 2023 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies AL Amyloidosis Therapeutics revenues in global market, 2019-2024 (estimated), ($ millions)
Key companies AL Amyloidosis Therapeutics revenues share in global market, 2023 (%)
Further, the report presents profiles of competitors in the market, key players include:
Janssen Pharmaceutical
Prothena
Alexion Pharmaceuticals
Oncopeptides AB
Bristol-Myers Squibb
GlaxoSmithKline Pharmaceuticals Ltd
Eidos Therapeutics, Inc.
Corino Therapeutics, Inc.
Spectrum Pharmaceuticals, Inc.
Pfizer
Outline of Major Chapters:
Chapter 1: Introduces the definition of AL Amyloidosis Therapeutics, market overview.
Chapter 2: Global AL Amyloidosis Therapeutics market size in revenue.
Chapter 3: Detailed analysis of AL Amyloidosis Therapeutics company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of AL Amyloidosis Therapeutics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
